TFF Pharmaceuticals, Inc. provided an update from the Company's ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection. Program update: The Phase 2 study now has 10 patients enrolled and 6 out of 6 patients who completed the 12-week treatment period with TFF TAC have chosen to remain on the therapy by proceeding to the safety extension phase. 1 patient has been treated for over a year and 3 additional patients have been treated for more than 6 months; PK data from first patient cohort indicate that TFF TAC dosing results in reduced systemic variability of tacrolimus; the systemic tacrolimus trough to peak concentration swings that occur with oral tacrolimus are not present with TFF TAC, which is predicted to reduce the risk of acute rejection and systemic toxicities such as chronic kidney disease, respectively; Patients on TFF TAC have provided anecdotal feedback to investigators noting a reduction in headaches, overall improvements in wellness, and/or ease of use in administration.